Trial reportBioMed research international2013
Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery.
Trial report in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2024Pooled it
- Adjunctive Therapies for Bacterial Keratitis.Middle East African journal of ophthalmologyPooled it
- The efficacy of autologous serum in corneal healing following metallic foreign body injuries.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Trial
- Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial.BMJ open ophthalmology · 2024Trial
- Amniotic membrane transplantation combined with cryotherapy vs. lamellar keratoplasty for medically refractory peripheral ulcerative keratitis: a retrospective cohort study.Frontiers in medicine · 2026Article
- Blood Derivatives in the Therapy of Ocular Surface Diseases.International journal of molecular sciences · 2025Review
- Comparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease.Ophthalmology and therapy · 2025Article
- Topical Insulin Eye Drops: Stability and Safety of Two Compounded Formulations for Treating Persistent Corneal Epithelial Defects.Pharmaceutics · 2024Article
- Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review.Bioengineering (Basel, Switzerland) · 2023Review
- Autologous Platelet and Extracellular Vesicle-Rich Plasma as Therapeutic Fluid: A Review.International journal of molecular sciences · 2023Review
- New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis.Frontiers in pharmacology · 2022Review
- Equine Umbilical Cord Serum Composition and Its Healing Effects in Equine Corneal Ulceration.Frontiers in veterinary science · 2022Article
- Article
- The use of autologous serum eye drops for the treatment of ocular surface disorders.European journal of hospital pharmacy : science and practice · 2019Article
- Stability of epidermal growth factor, fibronectin, and alpha-2-macroglobulin in canine serum under different storage conditions.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2019Article
- Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.Journal of clinical medicine · 2019Review
- Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits.Journal of clinical medicine · 2019Review
- Platelet lysate promotes re-epithelialization of persistent epithelial defects: a pilot study.International ophthalmology · 2019Article
- The corneal epitheliotrophic abilities of lyophilized powder form human platelet lysates.PloS one · 2018Article
- Application of Novel Drugs for Corneal Cell Regeneration.Journal of ophthalmology · 2018Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to investigate the efficacy and safety of topical 100% serum eye drops for corneal epithelial defect after ocular surgery. A total of 181 patients who received topical 100% serum therapy for the treatment of corneal epithelial defect following several different types of ocular surgery were recruited into this study. Each patient already failed conventional medical therapy before being prescribed 100% serum eye drops. Slit-lamp biomicroscopic examination with fluorescein staining was performed at baseline and all follow-up visits. The main outcome measures were the rate of complete healing of the corneal epithelial defect and incidence of adverse events. One hundred and seventy-eight eyes (98.34%) received autologous serum eye drops, and 3 (1.66%) received allogeneic serum eye drops. The overall success rate of treating persistent postoperative epithelial defect using 100% serum eye drops was 93.92% (95% CI 0.88-0.98). The median time to complete corneal epithelialization was 4 days (95% CI 4-5). Adverse reactions were observed in 3 patients (1.66%), including sticky sensation with minimal eye discomfort and asymptomatic trace corneal subepithelial infiltration. No serious complications were reported. In conclusion, 100% serum eye drops are effective, safe, and tolerable for treating postoperative corneal epithelial defect following ocular surgeries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.